Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00102258 · ClinicalTrials.gov registry record · Phase 2

Role of Nutrition and Hormones in Boys With Disordered Growth

A Phase 2 study, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Completed
Registry status
Phase 2
Development phase
20
Enrollment target

NCT00102258 is a Phase 2 study that has completed, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00102258, a Phase 2 study, has completed, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target

Study Summary

This study will determine whether adding more calories to the diet helps boys with growth problems grow better while being treated with Nutropin, a growth hormone that is used to help children grow taller. The Food and Drug Administration has approved Nutropin for use in children who are very short. This study will examine whether giving nutritional supplements in addition to Nutropin can help children grow better than with Nutropin alone. Boys between 7 and 10 years of age who are very short and below average in weight, but are otherwise healthy may be eligible for this study. Candidates must qualify for Nutropin treatments to boost their growth. Boys will be recruited for the study from the Nemours Children's Clinic in Jacksonville, FL, and from the National Institutes of Health in Bethesda, MD. Participants are randomly assigned to one of two treatment groups. One group is observed for 6 months and then receives a Nutropin injection every day for 12 months. The second group drinks 8 ounces of a high-calorie beverage called Pediasure every day for 6 months and then receives Nutropin plus Pediasure every day for 12 months. In addition to treatment, participants undergo the following tests and procedures at the schedule indicated: Baseline, 3, 6, 9, 12, 15 and 18 months * Clinical examination * Height measurement * Body composition assessment: Skin-fold thickness calipers are used in four places on the body to estimate body fat * Bioelectric impedance: A small amount of electrical current is used to calculate the percentage of body fat. Baseline, 6, 12, and 18 months * Blood tests * Bone age x-ray: x-ray of the left hand to measure growth potential * DEXA (dual energy x-ray absorptiometry) scan: x-ray scan to measure body fat, muscle, and bone mineral content. The subject lies on a flat table during the scan. Baseline, 6, and 12 months * Record of dietary intake: Parents are asked to write down everything the child eats and drinks for 3 days. Using this recor

Interventions

  • DRUG Growth Hormone Therapy

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2005-01-19
Est. Completion 2007-10-02
Phase Phase 2

What the Registry Record Tells You About NCT00102258

The ClinicalTrials.gov registry entry for NCT00102258 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Growth Hormone Therapy is the first listed.

NCT00102258 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00102258 about?

NCT00102258 is a clinical study titled "Role of Nutrition and Hormones in Boys With Disordered Growth". This study will determine whether adding more calories to the diet helps boys with growth problems grow better while being treated with Nutropin, a growth hormone that is used to help children grow taller. The Food and Drug Administration has approved Nutropin for use in children who are very short....

What is the current status of trial NCT00102258?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2005-01-19. Estimated completion is 2007-10-02.

What interventions are being tested in trial NCT00102258?

The interventions under investigation include: Growth Hormone Therapy (DRUG).

Who is sponsoring clinical trial NCT00102258?

This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.